Avidity Biosciences Stock (NASDAQ:RNA)
Previous Close
$26.68
52W Range
$21.51 - $56.00
50D Avg
$30.27
200D Avg
$38.18
Market Cap
$3.10B
Avg Vol (3M)
$1.52M
Beta
1.01
Div Yield
-
RNA Company Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
RNA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| SWTX | SpringWorks Therapeutics, Inc. |
| PASG | Passage Bio, Inc. |
| ARVN | Arvinas, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| IGMS | IGM Biosciences, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |